Melanoma is the most serious form of skin cancer. The Hope Foundation invests in melanoma research to advance immunotherapy, targeted therapy, and early detection methods, helping researchers find better ways to treat and prevent this aggressive disease.
SWOG Trial Finds a Three-Drug Combination May Offer Better Control of Melanoma That Has Spread to the Brain
A SWOG clinical trial called S2000 tackled one of the most difficult situations in melanoma treatment: cancer that has spread to the brain and is causing symptoms. Presented as a late-breaking oral abstract at the 2025 ASCO Annual Meeting, this is the first randomized trial ever conducted specifically in patients with symptomatic melanoma brain metastases, a group that has historically been excluded from clinical trials and has experienced very poor outcomes.
S2000 enrolled patients whose melanoma harbored a specific genetic change called a BRAF V600 mutation and which present in roughly half of all melanomas. This mutation is important because it can be targeted directly with drugs called BRAF and MEK inhibitors, in addition to immunotherapy. The trial compared a three-drug “triplet” regimen – combining two targeted therapy drugs (encorafenib and binimetinib) with the immunotherapy drug nivolumab – against the current standard two-drug immunotherapy combination of ipilimumab and nivolumab.
Findings:
The triplet combination produced a median progression-free survival of 6.2 months compared to 1.5 months with the standard two-drug immunotherapy regimen. The six-month progression-free survival rates were 54% with the triplet versus 20% with the doublet. When looking specifically at disease control within the brain, the difference was even more pronounced.
For patients whose melanoma carries the BRAF mutation, knowing that genetic status early could help guide treatment decisions. This trial adds meaningful evidence that a targeted-plus-immunotherapy approach may offer better disease control than immunotherapy alone.
The Hope Foundation for Cancer Research was honored to support this work by providing related salary support for study lead Zeynep Eroglu, MD, via a 2020 Coltman Fellowship.